ALFA FinderNSE filing, NSE: MPHASIS. Summary written from the filing by ALFA Finder's alert engine.
Mphasis Ltd: key numbers
- Share price
- ₹2,390.00
- Market cap
- ₹45,428 Cr
- Revenue (annual)
- ₹15,880 Cr
- Net profit (annual)
- ₹1,863 Cr
- P/E (TTM)
- 22.7×Sector 23.6×
- Promoter holding
- 30.53%-0.01% QoQ
- FII holding
- 19.39%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mphasis Ltd
All →Mphasis Investor Presentation: Key Takeaways
Q2 FY27: Direct revenue +11.3% YoY cc, +3.5% QoQ; net new TCV $466M; pipeline +23% YoY. FY27 revenue guidance raised to low double digits; margins ~14.8%.
Mphasis Employee Stock Options
Mphasis allotted 1,52,891 equity shares on exercise of ESOPs and RSUs under its 2016 and 2021 plans. No share price or cash consideration is stated, so no rupee value is attached.
Mphasis Business Update
Mphasis's board approved amendments to its Code of Practices and Procedures for Fair Disclosure of UPSI. The amended code is published on the company website.
Mphasis Q2 FY27 Results: Net Profit ₹561.1 Cr, Up 19.6% YoY
Mphasis Ltd reported revenue from operations of ₹4,581 Cr (+17.4% YoY) and net profit of ₹561.1 Cr (+19.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹561.1 Cr · +19.6% YoY
Mphasis Other Announcement
Mphasis received SBTi validation of its near-term and net-zero emissions targets. The company targets net-zero GHG by FY 2050 with 66% Scope 1+2 cuts by FY 2036.
Mphasis Legal & Regulatory
Mphasis reported a revised income tax demand of ₹2,417.80 crore following a rectification order, up from the previously disclosed ₹2,286.86 crore.
- Value
- ₹2,418 Cr
Other product launch announcements
All →Jeena Sikho Lifecare Product Launch
Jeena Sikho Lifecare launched ten new Ayurvedic healthcare products in the domestic market on November 11, 2026. The filing gives product-wise details under SEBI product-launch disclosure rules.
HCL Technologies Product Launch
HCLTech launched a pre-configured semiconductor PLM solution built on PTC Windchill, developed in collaboration with PTC. The release states no contract value or deal size, and the launch is a new product offering.
Morepen Laboratories Product Launch
Morepen launched Desloratadine Tablets USP 5 mg, its first US prescription generic, through subsidiary Morepen Bio Inc. It also filed a Sitagliptin ANDA with the US FDA.
AstraZeneca Pharma India Product Launch
AstraZeneca Pharma India will launch Datverzo, Datopotamab Deruxtecan, in India in November 2026. The drug holds DCGI import and market permission for HR-positive, HER2-negative breast cancer.
Raama Finance Product Launch
Raama Finance launched 'Rupya Lelo', a digital lending platform offering instant personal loans, on October 6, 2026. The product is available only in India, and no loan amount or financial figure is disclosed.
Puravankara Product Launch
Puravankara will launch the residential project Purva Cityspire Phases 1, 2 and 3 in Ernakulam on 15 November 2026. The project is RERA-registered and is being developed by two wholly owned subsidiaries.